Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder

Phase 2 Completed 12 enrolled New York State Psychiatric Institute COMPASS Pathways · collab University of California, Los Angeles · collab

NaSingle-groupOpen-labelTreatment

Summary

In this pilot study 12 adult outpatients with body dysmorphic disorder that has not responded to at least one adequate trial of a serotonin reuptake inhibitor will be treated openly with a single oral dose of psilocybin. Followup visits to monitor safety and clinical outcome will be conducted over a 3 month period.

Timeline

Start: 2021-02-26
Primary completion: 2022-11-02
Completion: 2022-11-02

Publications

Zhu X, Zhang C, Hellerstein D, Feusner JD, Wheaton MG, Gomez GJ, Schneier F. Single-dose psilocybin alters resting state functional networks in patients with body dysmorphic disorder. Psychedelics (N Y). 2025;1(1):25-31. doi: 10.61373/pp024r.0028. Epub 2024 Sep 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Psilocybin	Other / unclassified	25 mg	Oral

Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder

Summary

Timeline

Publications

Drugs

Indications